GlaxoSmithKline’s COPD drug Anoro receives European green light

[Reuters] – Anoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday. It is expected to generate sales of more

View todays social media effects on THRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Theravance is hiring next, click here to view